Combining eloralintide with tirzepatide increases weight loss
Healio reports phase 2 trial data, presented at the European Association for the Study of Diabetes meeting, in 367 adults with type 2 diabetes and overweight or obesity. Over 48 weeks, the investigational amylin agonist eloralintide plus tirzepatide produced weight loss of up to 23.3%, versus 14.8% with tirzepatide 15 mg alone. Gastrointestinal side effects were most common. The Lilly-funded trial precedes a planned phase 3 study.
Why it matters: Relevant to Maryland adults with type 2 diabetes and overweight or obesity exploring medical weight loss, and to clinicians who refer them for metabolic care.
A summary of another publisher's reporting, written with AI and checked automatically against the story. The reporting belongs to healio.com. October 3, 2026.